Opinion: The Aduhelm Operetta: ‘I’ve got a little list’
The Congressional report on the FDA’s approval of Aduhelm makes some good points. As regulatory science advances, so too must the FDA’s administrative procedures.
But this report mustn’t be seen as an excuse for the agency to hew to a 20th century view of drug development and review. The FDA and the industries it regulates must work together to facilitate innovation that results in new and important medical technologies like Aduhelm and other medicines currently in the pipeline for Alzheimer’s disease and other serious and life-threatening conditions.
Read Original Article: Opinion: The Aduhelm Operetta: ‘I’ve got a little list’ »
